Republished: Severe acute ocular hypertension following pulsed methylprednisolone for juvenile idiopathic arthritis

Andrew Beverstock,1 Alison Kelly2
1Department of Paediatric Orthopaedics, Bristol Royal Hospital for Children, Bristol, UK
2Department of Paediatric Rheumatology, Bristol Royal Hospital for Children, Bristol, UK
Correspondence to: andrew.beverstock@uhbristol.nhs.uk


In conjunction with BMJ Case Reports, DTB will feature occasional drug-related cases that are likely to be of interest to readers. These will include cases that involve recently marketed drugs for which there is limited knowledge of adverse effects and cases that highlight unusual reactions to drugs that have been marketed for several years.

Summary
We report the case of a 6-year-old girl with juvenile idiopathic arthritis and anterior uveitis who was treated with two doses of intravenous methylprednisolone for acute arthritis. She developed severe ocular hypertension (intraocular pressures (IOPs) of 54 mm Hg in the right eye and 61 mm Hg in the left eye) requiring inpatient therapy with intravenous acetazolamide. The normal range of values for IOP is 12–22 mm Hg. This severe case of acute intraocular hypertension due to systemic steroids highlights the need to consider monitoring of IOPs for children on high-dose topical and systemic steroids with risk factors for raised IOP.

Background
Ocular hypertension is a well-recognised side-effect of topical and systemic corticosteroid therapy, but the majority of patients have a mild rise in intraocular pressure (IOP) of less than 20 mm Hg which after withdrawal of steroids without the need for any additional treatment.1 The effect is more common with topical corticosteroid therapy.

This case is significant due to the rapid onset of the ocular hypertension and the severity of the rise. No report of such significantly elevated pressures after pulsed intravenous steroid therapy in such a young patient has been published. The case highlights the need to consider monitoring of IOPs following pulsed systemic steroids: in this case, the ocular hypertension was detected incidentally.

Case presentation
This patient was diagnosed with oligoarticular juvenile idiopathic arthritis (JIA) at age 3 following a 1-year history of left knee stiffness. Her JIA predominantly affected her left knee, left ankle and cervical spine. She was treated initially with intravenous methylprednisolone in 2012 to achieve remission before commencing maintenance methotrexate. She was screened on a six monthly basis for uveitis over the next 2 years and had no evidence of uveitis in this time. IOPs were not routinely measured.

She was diagnosed with bilateral anterior uveitis on the 2015 on routine screening and was commenced on Pred Forte (prednisolone acetate 1% weight/volume) drops six times daily to both eyes. IOPs were not recorded due to patient distress at the time of examination. The following week, she was treated with 1000 mg intravenous methylprednisolone as a day case for a flare-up of her neck symptoms of JIA, and she was due to return the following day for a second dose. On the day her second dose was due, her mother found her to be sleepier than usual, but no visual symptoms were reported.

She had a follow-up with the ophthalmologists arranged on the same day prior to attending the hospital for her second steroid intravenous infusion. Routine tonometry was performed using iCare tonometry at this appointment. This showed significant elevation of her IOPs, with a pressure of 53.6 mm Hg in the right eye and 61.2 mm Hg in the left eye. These measurements were repeatable. Ocular examination revealed mild anterior chamber activity with 0.5+ cells in both anterior chambers.

The follow-up had been arranged prior to the administration of her systemic steroids, and thus her ocular hypertension contributed to by the intravenous methylprednisolone was picked up almost incidentally rather than through specific screening.

Treatment
Due to her extremely high IOPs, the patient was admitted for intravenous acetazolamide and topical antihypertensive therapy. After a single dose of intravenous acetazolamide her pressures improved to 25 mm Hg in the right eye and 35 mm Hg in the left eye. After two further doses her pressures were 17 mm Hg bilaterally, within the normal range. She was commenced on...
topical timolol, latanoprost and brinzolamide, and 7 days later, her pressures were 14 mm Hg bilaterally.

Systemic steroids were discontinued, and she was commenced on adalimumab for long-term control of her arthritis and uveitis.

**Outcome and follow-up**

Her pressures remained low at 12 mm Hg bilaterally on long-term follow-up. Topical therapy was discontinued in January 2016 and her IOPs remained normal. Her uveitis was well controlled on adalimumab with no side effects. She had close follow-up for the next 3 years, and her IOPs remain normal.

She received an intra-articular injection of 30 mg triamcinolone acetonide but had normal IOPs before and 48 hours after the procedure.

**Discussion**

Mild intraocular hypertension is a well-described side effect of both topical and systemic corticosteroid therapy: mild rises in IOP occur in up to 60% of patients, but significant rises are uncommon. Risk factors for raised IOP following steroid administration include a previous history of uveitis, comorbid connective tissue disease and younger age. Severe intraocular hypertension can be vision threatening but is frequently asymptomatic; therefore, early recognition and management is important.

Our case is noteworthy for several reasons: the severity of the ocular hypertension, the rapid speed of onset following the administration of intravenous steroids and due to its asymptomatic nature, being discovered almost incidentally. A previous published case described a patient with symptoms (headaches, eye pain, reduced visual acuity), while another described the onset following several months of therapy, but none described such markedly raised pressures in an asymptomatic patient.

Additionally this case highlights that significant intraocular hypertension can present very differently in children. Adults with such significant rises in IOP typically present with headaches and visual disturbance. The patient in this case was only fatigued, and raised pressures in an asymptomatic patient.

This patient developed severe ocular hypertension due to a combination of her topical prednisolone drops and pulsed intravenous methylprednisolone therapy. It is not possible to determine the precise contribution of each to her ocular hypertension, but it is likely that the severity of her ocular hypertension was related to the combination of both routes of administration. She developed this condition within 3 weeks of commencing topical steroid therapy. Had she not been followed-up for her uveitis the high pressure may have been missed. Routine measurement of IOP for patients receiving topical and intravenous steroid therapy with risk factors may be advisable to allow early detection and management of this condition.

**Learning points**

- Steroid-induced ocular hypertension can occur in patients with juvenile idiopathic arthritis treated with systemic steroids.
- It is usually asymptomatic and can be easily missed without screening. This puts patients at risk of sight-threatening glaucomatous optic neuropathy.
- Consider screening for ocular hypertension following pulsed intravenous methylprednisolone therapy, especially in patients using topical ocular steroids.

**Contributors**

AB wrote initial draft. AK amended the draft and approved the final version.

**Funding**

The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests**

None declared.

**Patient consent for publication**

Parental/guardian consent obtained.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Open access**

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

**References**


**DOI:** 10.1136/dtb.2019.229803rep